Top

Published in:

01-11-2012 | Laboratory Investigation

miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas

Authors: Lei Shi, Dongyi Jiang, Guan Sun, Yi Wan, Shuguang Zhang, Yanjun Zeng, Tianhong Pan, Zhimin Wang

Published in: Journal of Neuro-Oncology | Issue 2/2012

Abstract

Meningiomas, one of the most common benign brain tumors in humans, arise from arachnoid cells in the brain meninges. Our investigations have revealed that miR-335 is a typical microRNA overexpressed in meningiomas in humans. Characterization of the effects of miR-335 overexpression in meningiomas demonstrated that elevated levels of miR-335 increased cell growth and inhibited cell cycle arrest in the G0/G1 phase in vitro; in addition, reduction of the miR-335 levels had the opposite effect on tumor growth and progression. Further, previous studies have shown that the mechanism of effect of miR-335 on the proliferation of meningioma cells is associated with alterations in the expression of human retinoblastoma 1 (Rb1). Our results indicate that miR-335 plays an essential role in the proliferation of meningioma cells by directly targeting the Rb1 signaling pathway. Thus, our results highlight a novel molecular interaction between miR-335 and Rb1, and miR-335 may represent a potential novel therapeutic agent to target the proliferation of meningioma cells.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) World Health Organization classification of tumours of the central nervous system. IARC Press, Lyon

Zhang X, Gejman R, Mahta A, Zhong Y, Rice KA, Zhou Y, Cheunsuchon P, Louis DN, Klibanski A (2010) Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res 70:2350–2358PubMedCrossRef

Wen PY, Yung WKA, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, DeAngelis LM, Mehta M, Tomaso ED, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD (2009) Phase II study of imatinib mesylate for recurrent meningiomas (North American brain tumor consortium study 01–08). Neuro Oncology 11:853–860PubMedCrossRef

Chen CZ (2005) MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353:1768–1771PubMedCrossRef

Saydam O, Shen Y, Würdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM, Breakefield XO (2009) Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing e-cadherin and activating the Wnt/β-catenin signaling pathway. Mol Cell Biol 29:5923–5940PubMedCrossRef

Scarola M, Schoeftner S, Schneider C, Benetti R (2010) miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response. Cancer Res 70:6925–6933PubMedCrossRef

Shu M, Zheng X, Wu S, Lu H, Leng T, Zhu W, Zhou Y, Ou Y, Lin X, Lin Y, Xu D, Zhou Y, Yan G (2011) Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. Mol Cancer 10:59PubMedCrossRef

Chen C, Wu CQ, Zhang ZQ, Yao DK, Zhu L (2011) Loss of expression of miR-335 is implicated in hepatic stellate cell migration and activation. Exp Cell Res 317(12):1714–1725PubMedCrossRef

Tome M, Lopez-Romero P, Albo C, Sepulveda JC, Fernandez-Gutierrez B, Dopazo A, Bernad A, Gonzalez MA (2011) miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ 18(6):985–995PubMedCrossRef

10.

Darling JL (1990) The in vitro biology of human brain tumors. In: Thomas DGT (ed) Neuro-oncology: primary malignant brain tumors. Johns Hopkins University Press, Baltimore Md, pp 1–25

11.

Chang SF, Chang TK, Peng HH, Yeh YT, Lee DY, Yeh CR, Zhou J, Cheng CK, Chang CA, Chiu JJ (2009) BMP-4 induction of arrest and differentiation of osteoblast-like cells via p21CIP1 and p27KIP1 regulation. Mol Endocrinol 23:1827–1838PubMedCrossRef

12.

Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433:769–773PubMedCrossRef

13.

Mack PC, Chi SG, Meyers FJ, Stewart SL, deVere White RW, Gumerlock PH (1998) Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade. Prostate 34:145–151PubMedCrossRef

14.

Ronchetti D, Lionetti M, Mosca L, Agnelli L, Andronache A, Fabris S, Deliliers GL, Neri A (2008) An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics 1:37PubMedCrossRef

15.

Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ (2010) Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 11:50–54PubMedCrossRef

16.

Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451:147–152PubMedCrossRef

17.

Classon M, Harlow E (2002) The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2:910–917PubMedCrossRef

18.

Marsh EE, Lin Z, Yin P, Milad M, Chakravarti D, Bulun SE (2008) Differential expression of microRNA species in human uterine leiomyoma versus normal myometrium. Fertil Steril 89:1771–1776PubMedCrossRef

19.

Swiss VA, Casaccia P (2010) Cell-context specific role of the E2F/Rb pathway in development and disease. Glia 58:377–390PubMed

20.

Du W, Searle JS (2009) The rb pathway and cancer therapeutics. Curr Drug Targets 10:581–589PubMed

21.

Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113:703–716PubMedCrossRef

22.

Knudsen ES, Wang JY (2010) Targeting the RB-pathway in cancer therapy. Clin Cancer Res 16:1094–1099PubMedCrossRef

Title: miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas
Authors: Lei Shi
Dongyi Jiang
Guan Sun
Yi Wan
Shuguang Zhang
Yanjun Zeng
Tianhong Pan
Zhimin Wang
Publication date: 01-11-2012
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2012
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-012-0951-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis

Chemosensitized radiosurgery for recurrent brain metastases

Limited utility despite accuracy of the national SEER dataset for the study of craniopharyngioma

Increased risk of cancer after Bell’s palsy: a 5-year follow-up study

Lack of MGMT promoter hypermethylation in hemangiopericytomas of the central nervous system

Validation of the Mishel’s uncertainty in illness scale-brain tumor form (MUIS-BT)